A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41
about
Domain Flexibility Modulates the Heterogeneous Assembly Mechanism of Anthrax Toxin Protective AntigenAn inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitorsHIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected]Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivityIncreased functional stability and homogeneity of viral envelope spikes through directed evolution.Chemokine receptor CCR5: from AIDS to atherosclerosisG protein-coupled receptors--recent advancesBiochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor designHigh-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry InhibitorsScreening and Functional Profiling of Small-Molecule HIV-1 Entry and Fusion Inhibitors.Amphipathic properties of HIV-1 gp41 fusion inhibitors.Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors.Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.Development of a rapid cell-fusion-based phenotypic HIV-1 tropism assayResistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at its Apex.
P2860
Q27675435-B7902213-C9FA-4499-8DB1-C299A441353EQ28477736-6F9FEBC4-599F-4737-A31B-8E5F2D016907Q28485218-456EB030-F3DB-497F-822C-4C686CF6DF76Q28485983-108D7F18-0CF4-4CF9-A96B-A05DF5368300Q34611144-9CFC231C-DBAC-4164-824D-A9C895265FB8Q34672038-76FF9FE3-2855-4FE0-833F-6046A5C66BE9Q35065927-5F7C014B-4A6E-49C7-A04B-3FF1D10A0FE4Q35563298-815A0CDB-3C7C-485C-A20E-5015F92CB735Q35600803-3073D71D-DD9C-4A4C-A95C-BC2A8ED2712CQ36316050-B2BDA1E8-8498-42A8-A240-040D81CBAC53Q37951610-853EFC71-AB0A-4376-960C-254B2C008B10Q38028795-45630AEB-3BC5-4FF9-823A-93B5B91E5B1DQ38076139-FD2AE472-FBD0-47D2-9BF4-D428CD5F64D7Q38196457-4762B57C-5216-41FB-9E49-455AAC07BD9CQ39094162-999FA44A-9841-4B48-B3A2-00B076AF5F77Q41857055-C5056B12-84CC-41FF-B5DB-F6362DD1B35FQ41924154-74907FA6-5DBC-44AF-8916-D617F23CAD60
P2860
A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A low-molecular-weight entry i ...... 1 targets a novel site on gp41
@ast
A low-molecular-weight entry i ...... 1 targets a novel site on gp41
@en
type
label
A low-molecular-weight entry i ...... 1 targets a novel site on gp41
@ast
A low-molecular-weight entry i ...... 1 targets a novel site on gp41
@en
prefLabel
A low-molecular-weight entry i ...... 1 targets a novel site on gp41
@ast
A low-molecular-weight entry i ...... 1 targets a novel site on gp41
@en
P2093
P2860
P356
P1433
P1476
A low-molecular-weight entry i ...... 1 targets a novel site on gp41
@en
P2093
Chris Pickford
Daniel P Leaman
Edward J Murray
Hannah Perkins
Manos Perros
Michael B Zwick
Nishant Pawa
Scott L Butler
P2860
P304
P356
10.1128/JVI.00535-10
P407
P577
2010-04-28T00:00:00Z